Hikma Pharmaceuticals (HKMPF) Stock Statistics & Valuation Metrics

Hikma Pharmaceuticals has a market cap or net worth of $4.08B. The enterprise value is $5.45B.

Hikma Pharmaceuticals has 213,320,770 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hikma Pharmaceuticals’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 10.49%.

The current PE Ratio of Hikma Pharmaceuticals is 10.5. Hikma Pharmaceuticals’s PEG ratio is 0.72.

In the last 12 months, Hikma Pharmaceuticals had revenue of 3.35B and earned 410.43M in profits. Earnings per share was 1.86.

In the last 12 months, operating cash flow was 389.94M and capital expenditures -195.38M, giving a free cash flow of 194.56M billion.

Hikma Pharmaceuticals pays an annual dividend of $0.48, resulting in a dividend yield of 3.99%

Hikma Pharmaceuticals upcoming earnings date is Aug 6, 2026, TBA (Confirmed).

Hikma Pharmaceuticals as a current ratio of 1.82, with Debt / Equity ratio of 63.59%

In the past 12 months, Hikma Pharmaceuticals has paid 114.35M in taxes.

Hikma Pharmaceuticals EV to EBITDA ratio is 6.95, with an EV/FCF ratio of 35.53.

Hikma Pharmaceuticals has $354.13M in cash and marketable securities with $1.60B in debt, giving a net cash position of -$1.25B billion.

Gross margin is 41.35%, with operating margin of 17.32%, and net profit margin of 12.26%.

The average price target for Hikma Pharmaceuticals is $24.28, which is 11.43% higher than the current price. The consensus rating is Moderate Buy